I was very pleased with the successful turnout at our first Grand Rounds of the year on Tuesday. I hope that you all enjoyed the new format for Rounds and that you will continue to fill the room each week. We will continue to hold Rounds in Brady Auditorium for the remainder of September and will evaluate attendance and determine if we should move to a larger space at that time. Additional lunches will be ordered to accommodate the increased attendance.
Please join me on Tuesday, September 22nd to listen to presentations by Francine Foss, MD and Melinda Irwin, PhD.
Learn More >>
Yale Cancer Center Welcomes Don Xuan Nguyen, PhD
We are pleased to announce that Don Nguyen will join the faculty of the Department of Pathology at Yale School of Medicine as an Assistant Professor. In his new role, Dr. Nguyen will be an active member of Yale Cancer Center.
In his current position, he is a postdoctoral fellow with Joan Massague at Memorial Sloan-Kettering Cancer Institute. Dr. Nguyen will continue his postdoctoral work, in which he has pioneered models to identify genes most important for human lung cancer metastasis. This work will help found two important new areas of research in YCC, the biology of tumor progression, and etiology and treatment of thoracic cancers.
The Yale School of Medicine Office of Institutional Planning and Communications is currently redesigning all of the faculty profile pages. Please take the time to edit the information on your profile to ensure it is both correct and complete. The new profiles will be used to populate all of the department websites, as well as Yale Cancer Center's site.
Learn More >>
As construction nears completion in the Lower Level for Radiation Oncology, functional units are finalizing their departmental operating plans. The Education & Orientation team is completing scripting for tours and orientation sessions, which will begin shortly. Construction workers are now completing the lobby, including finishing the floors, placing the lobby furniture, and installing a water feature.
Matthew Strout, MD, PhD,
has been awarded a K08 Career Development Award from the NCI. His research is focused on understanding the basic mechanism that regulates immune diversification in mature B cells and how it breaks down during pathogenesis of B cell leukemia and lymphomas. The total direct costs for the 5-year project period is $817,500.
New Clinical Trial Available
Principal Investigator: Madhav Dhodapkar, MD A Phase I/II Open-Label, Dose-Escalation Study of CDX-1401 in Patients with Malignancies Expressing NY-ESO-1
Update from Yale Pathology
Companion diagnostic tests are pathology-based tests where an assay is done on patient tissue to judge if that patient is a candidate for drug therapy. These tests have become an important part of patient management. Similarly, nearly all clinical trials are including studies of potential companion diagnostic tests alongside the tests of the new therapies.
Thus, as the Cancer Center increases its role and participation in multi-site clinical trials, it has become important to provide patient tissue samples for these trials. Many trials include signed patient consent for release of this material, but this was in conflict with compliance issues that require that the Department of Pathology maintain tissue blocks for 10 years. To respond to this need and mitigate this conflict, the Department of Pathology has established a new Standard Operating Procedure to provide tissue from formalin fixed, paraffin embedded tissue blocks. The tissue provided is a 4mm core, which is sufficient to meet most clinical trial tissue requirements, but allows maintenance of the block in the Pathology Archives for patient safety and to meet regulatory standards.
For more information, or to place a request, please contact Rose Piche.
If you have questions or concerns about the new procedures and services, please contact David Rimm, MD, PhD.
Major services of the MSR consist of gene expression and genotyping analysis using multiple platforms including Affymetrix, Illumina, NimbleGen, Sequenom, and ABI 7900. In addition to this, the MSR also provides high throughput DNA sequence analysis services using Illumina genome analyzer. The MSR assists in planning and carrying out microarray experiments; expression analysis services that include RNA/mRNA extraction, preparation of target samples suitable for array hybridization, and data analysis; SNP analysis using both Affymetrix (10,100 and 500 K assays) and ABI platforms; and quantitative PCR validation of microarray results using the ABI 7900 Sequence Detection System. The MSR also offers a range of spotted glass slide microarray services.